Mithra and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

  • Mithra grants license for its vaginal contraceptive ring to Gynial for commercialization in Switzerland
  • Strengthening its partnership with Women’s Health specialist Gynial, already responsible for the Austrian market
  • Large-scaled global commercialization of Myring™ after first successful launches in Europe

Liege, Belgium, 05 May 2020 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement (LSA) with Gynial GmbH for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

Mithra Announces Commercial Launch of Myring™ in Germany, the biggest market in Europe

  • Successful launch of Mithra’s hormonal contraceptive ring in Germany under the trademark MYCIRQ®
  • Germany is the largest European market and the second worldwide, with 3 million vaginal rings sold per year
  • Mithra CDMO pursues the manufacturing of its Myring™ orders in compliance with all the measures required by the Belgian authorities

Liege, Belgium, 2 April 2020 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the commercial launch of Myring™ in Germany, which is the largest European market and the second worldwide in terms of sales volume. With 3 million vaginal rings sold per year, the German contraceptive rings market is worth EUR 27 million per year.

 

Mithra Announces Commercial Launch of Myring™ in Belgium

  • Mithra’s hormonal contraceptive ring is now available in pharmacies in Belgium under the trademark name Myloop®
  • Large-scaled global commercialization of Myring™, especially in the world’s three largest markets
  • Mithra CDMO in Belgium expected to produce nearly 2 million rings in 2020

Liege, Belgium, 12 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the commercial launch of Myring™ in Belgium. The Belgian contraceptive ring market is valued at around EUR 5.1 million, with more than 600,000 rings sold each year. Mithra’s vaginal contraceptive ring is marketed by Ceres Pharma in Belgium under the trademark name Myloop®.

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market

  • Mithra grants a license to Farmitalia for commercialization of its vaginal contraceptive ring in Italy
  • Italy is the third largest worldwide contraceptive ring market with nearly 2 million vaginal rings sold per year
  • Mithra CDMO will launch the production of nearly 20,000 rings per month for the Italian market in the coming weeks

Liege, Belgium, 21 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement with Farmitalia for the commercialization of its hormonal contraceptive ring Myring™ in Italy.

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Italy

  • Mithra grant a license to Farmitalia for commercialization of its hormone treatment Tibelia® in Italy
  • Tibelia® is currently marketed in 13 countries through existing license and supply agreements
Liege, Belgium, 07 January 2020 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement with Farmitalia for the commercialization of Tibelia® in Italy.

Mithra Receives EUR 2.9 Million in Non-dilutive Funding

Liege, Belgium, 23 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted EUR 2.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by Mr Willy Borsus, Vice President of the Walloon Government and Minister of Economy, Foreign Trade, Research & Innovation, New Technologies, Agriculture and Urban and Spatial Planning.

Mithra and Searchlight sign LSA for Myring™ in Canada

  • Mithra grants exclusive license for vaginal contraceptive ring to Searchlight Pharma for commercialization in Canada
  • With Mithra’s two leading products Myring™ and Estelle®, Searchlight Pharma aims to further expand its growing footprint in Women’s Health

Liege, Belgium, 16 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Searchlight Pharma (Searchlight) for the commercialization of its hormonal contraceptive ring Myring™ in Canada.

Mithra Signs LSA for Commercialization of Myring™ in Switzerland

  • Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 05 December 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

European Authorities Approve Advantageous Modifications to Myring™ labelling

  • Removal of requirement for special temperature storage for vaginal contraceptive ring Myring™
  • Competitive advantage in terms of reduced costs and convenience for distributors, pharmacists and patients
  • Similar labelling to be pursued in the United States
Liege, Belgium, 08 November 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that the European Authorities has approved two noteworthy modifications relating to the change in the shelf-life and storage conditions of its vaginal contraceptive ring Myring.

Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe

  • Mithra grants exclusive license to Aicore Life Sciences for commercialization of Myring™ and Tibelia® in Eastern Europe
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 24 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Aicore Life Sciences for the registration and commercialization of two major products in contraception and menopause in Eastern Europe: the hormonal contraceptive ring Myring™ and the tibolone-based product Tibelia® for use in Hormone Therapy (HT).